Value-Based Care, Drug Costs, Gene Therapy, and Research Funding
This week’s BioBlog focuses on continued efforts toward Value-Based Care, expensive cancer drug costs, the impact that Donald Trump’s presidency will have on funding and research, and using gene therapy to help alleviate harmful affects of cancer treatment.
In their effort to continue moving toward a value-based care system, Moffitt Cancer Care has partnered with United Health to roll out a bundled treatment program for early stage lung cancer.
In this article, Fierce Healthcare reports that they expect once Trump takes office that most of the changes to the Affordable Care Act will happen on the financing of healthcare, rather than making changes to the way the care is actually delivered.
Reuters reports, in a surprising move the Japanese health council intervened by reducing the expensive cancer drug Opdivo.
ABC News reports that researchers involved in the use of embryonic stem cells and fetal tissue are waiting to find out if Donald Trump’s presidency will lead to new restrictions and changes in funding for their research.
This article highlights new research that has found using gene therapy can help reverse harmful effects on the heart in patients that received Doxorubicin treatment.